武田制药 TAK 深沪

等待开盘 05-11 09:30:00 美东时间

16.485

-0.155

-0.93%

华盛通

立即下载

最高16.92
今开16.66
成交量 402.18万股
最低 16.48
昨收 16.64
总市值 5118.59万
52周最高 18.895
市盈率 ^静 25.40
换手率 129.53%
52周最低 12.99
委比 -79.12%
总股本 0.03亿
历史最高 19.2183
量比 1.64
振幅 2.64%
历史最低 10.584
每手 1
风险率 1.53%

个股概要

财务分析

公司资料

分红派息

分时图
日k
周k
月k

相关新闻

中国创新药出海，如何从“能出去”到 “走得远”？

转自：中国新闻网　　在全球医药创新的浪潮中，中国创新药正以前所未有的姿态登上世界舞台。2026年政府工作报告提出“推动创新药和医疗器械高质量发展”，为行业升级...

04-29 16:40
ASCO前夜，信达引爆PD-1/IL-2浪潮

（来源：商图药讯） bioseedin柏思荟作者：GA PREFACE 前言当地时间5月29日至6月2日，美国临床肿瘤学会（...

04-28 19:30
信达生物近10年首盈8.14亿或迎拐点携手全球巨头商业开发成交220亿美元

长江商报消息 ●长江商报记者沈右荣中国生物制药领先企业信达生物（01801.HK）终于盈利了，或将是公司业绩拐点。近期，信达生物发布的年度业绩公告显示，...

04-20 07:21
Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda

Axsome gains after securing global rights to balipodect from Takeda, advancing schizophrenia pipeline amid bullish analyst targets.

04-02 01:36
当年报披露遭遇商业化品种撤市，和黄医药(00013)何时打破“200亿估值魔咒”？

3月5日，和黄医药(00013)披露公司2025年年报业绩，其中公司当期股东应占溢利同比增长1111.03%，表现亮眼。随后大华继显、美银证券和里昂等机构纷纷...

03-10 23:27
创新药BD交易进入“后签约时代”，潜在风险初现端倪

作者/韩利明 2025年，中国创新药行业迈入新十年发展周期，BD（商务拓展）交易持续升温，行业出海势能加速释放。国家药监局数据显示，全年中国创新药BD交...

02-10 18:15
Takeda Flags Vyvanse Hit, Lifts 2025 Profit Guidance On Cost Control

Takeda missed Q3 earnings estimates as Vyvanse generic pressure weighed on sales, but raised its 2025 profit forecast on cost discipline and favorable currency moves.

01-29 22:11
Earnings Scheduled For January 29, 2026

Companies Reporting Before The Bell • MOGU (NYSE:MOGU) is estimated to report e...

01-29 19:11
Takeda Pharmaceutical Co Lowers FY2025 GAAP EPS Guidance from $0.66 to $0.64; Lowers FY2025 Sales Guidance from $30.524B to $29.409B

Takeda Pharmaceutical Co (NYSE:TAK) lowers FY2025 GAAP EPS guidance from $0.66 to $0.64. Lowers FY2025 sales outlook from $30.524 billion to $29.409 billion.

01-29 15:58
Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle

CMS selects 15 high-cost prescription drugs for Medicare drug price negotiation program, expanding to include Part B drugs.

01-28 18:51

派息除权日	每股总股息	派息日期
2022-03-30	0.36	2022-03-30
2021-09-29	0.39	2021-09-29
2021-03-30	0.40	2021-03-30
2020-09-29	0.38	2020-12-11
2020-03-30	0.32	2020-07-06
2019-09-27	0.32	2019-12-12
2019-03-27	0.36	2019-06-28
2018-09-26	0.30	2018-12-01
2018-03-27	0.30	2018-07-09
2017-09-27	0.31	2017-12-01
2017-03-29	0.36	2017-07-10
2016-09-28	0.29	2016-12-12
2016-03-29	0.32	2016-07-11
2015-09-28	0.28	2015-12-11
2015-03-27	0.33	2015-06-01
2014-09-26	0.29	2014-12-11
2014-03-27	0.37	2014-06-30
2013-09-26	0.43	2013-12-01
2013-03-27	0.45	2013-06-01
2012-09-26	0.55	2012-09-26
2012-03-28	0.50	2012-07-09
2011-09-28	0.51	2011-12-12
2011-03-29	0.49	2011-07-07
2010-09-27	0.50	2010-12-13
2010-03-29	0.45	2010-07-14
2009-09-25	0.46	2009-12-15
2009-03-26	0.42	2009-07-14
2008-09-25	0.41	2008-12-16
2008-03-26	0.36	2008-03-26

公司名称	Takeda Pharmaceutical Co., Ltd.
行业分类	Pharmaceuticals: Major
业务描述	Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

武田制药 TAK 深 沪

16.485

个股概要

财务分析

公司资料

相关新闻

分红派息

相关新闻

公司简介

武田制药 TAK 深沪